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1,3-Butadiene is a major industrial chemical that has been shown to be a carcinogen at multiple sites in mice and rats at concentrations as low as
6.25 ppm. Occupational exposures have been reduced in response to these findings, but it may not be possible to determine by using traditional
epidemiological methods, whether current exposure levels are adequate for protection of worker health. However, it is possible to evaluate the bio-
logical significance of exposure to genotoxic chemicals at the time of exposure by measuring levels of genetic damage in exposed populations. We
have conducted a pilot study to evaluate the effects of butadiene exposure on the frequencies of lymphocytes containing mutations at the hypoxan-
thine-guanine phosphoribosyl transferase (hprt locus in workers in a butadiene production plant. At the same time, urine specimens from the same
individuals were collected and evaluated for the presence of butadiene-specific metabolites. Eight workers from areas of the plant where the high-
est exposures to butadiene occur were compared to five workers from plant areas where butadiene exposures were low. In addition, six subjects
with no occupational exposure to butadiene were also studied as outside controls. All of the subjects were nonsmokers. An air sampling survey con-
ducted for 6 months, and ending about 3 months before the study, indicated that average butadiene levels in the air of the high-exposure areas
were about 3.5 ± 7.5 ppm. They were 0.03 ± 0.03 ppm in the low-exposure areas. Peripheral blood lymphocytes from the subjects were assayed
using an autoradiographic test for hprt mutations. The weighted mean variant (mutant) frequency (Vf) (± SE) in the eight exposed subjects was
3.84(±0.70) x 106 per evaluatable cell, as compared to 1.16±(0.27) x 104 in the low-exposed and 1.03(±0.07) x 106 in the outside controls. The Vf of
the low-exposed controls and the outside controls were not significantly different, but the mean frequency of mutant lymphocytes in the seven
exposed subjects was significantly higher when compared to the mean Vf of the nonexposed controls (p<0.01) and the low-exposed controls
(p<0.05). A single metabolite of butadiene, 1,2-dihydroxy-4-(N-acetlylcysteinyl-S) butane, was detected in the urine of all subjects. The concentration
in the urine of the workers in the high-exposed group was significantly greater than in the low-exposed or nonexposed groups. The correlation
between the level of the metabolite in urine and the frequency of hprt mutants was r = 0.85. The observation of an elevated Vf in the exposed sub-
jects and the strong correlation of Vf with the level of excreted metabolite suggests that butadiene exposures under these conditions were suffi-
cient to induce somatic cell mutations. This degree of increase in Vf is similar to what we have observed in cigarette smokers. The results available
at this time indicate that current levels of occupational exposure to butadiene may not be sufficiently low to protect workers from the adverse
effects that may result from exposure to mutagens. - Environ Health Perspect 102(Suppl 9):79-85 (1994)
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Introduction
1,3-Butadiene (CAS no. 106-99-0) is used
in the manufacture of styrene-butadiene
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rubber, polybutadiene, and other polymers.
It ranks 34 in production in the United
States among commodity chemicals, with
total production in 1987 of 2.7 billion
pounds (1). Approximately 65,000 U.S.
workers are engaged in jobs in which there
is some level ofexposure to butadiene (2).
In chronic studies, 1,3-butadiene is carcino-
genic to laboratory animals. Lifetime expo-
sures of mice to as little as 6.25 parts per
million (ppm) ofbutadiene induced signifi-
cant increases in lung tumors, and at 625
ppm, lethal lymphomas occurred in most of
the animals (3). In rats, tumors were
observed in multiple organs ofboth sexes of
animals treated at 8000 ppm and tumors
were significantly increased in the mam-
maryglands offemales at 1000 ppm (4). At
comparable exposure levels the incidence of
tumors was higher in mice than in rats.
Butadiene is genotoxic in several in
vitro test systems. It induced base substitu-
tion mutations in Salmonella strains
TA1530 and 1535 after exogenous meta-
bolic activation (5). Sister chromatid
exchanges were induced in human lympho-
cytes exposed to butadiene, with or with-
out exogenous metabolic activation, when
the agent was added directly to the culture
medium (6) but not when cells were
exposed to an atmosphere containing buta-
diene (7). Sister chromatid exchanges were
also induced in Chinese hamster ovary cells
when the chemical was added to the
medium together with a metabolic activa-
tion system (8). The mono- and diepoxide
derivatives ofbutadiene are directly geno-
toxic in a variety ofshort-term test systems
(5,6,8). These derivatives are thought to be
the intermediates largely responsible for the
genetic toxicity ofbutadiene. In vivo stud-
ies have also demonstrated that butadiene
is genotoxic to cells in the bone marrow of
mice and rats (9-13).
Several epidemiological evaluations of
workers in butadiene production facilities
and in styrene-butadiene rubber (SBR)
plants have been published and recently
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critiqued (14). Recent studies (15-17)
have shown a consistent increase in mortal-
ity from lymphatic and hematopoietic
malignancies. Variability has been observed
in the specific types ofcancers and in the
response in relation to the duration of
exposure. However, it has been concluded
that there is at least limited evidence that
butadiene is carcinogenic to man (14).
Although the permitted exposure level
(PEL) established by the Occupational
Safety and Health Administration (OSHA)
for 1,3-butadiene is 1000 ppm, current lev-
els of occupational exposure are much
lower (2). The existing epidemiological
studies reflect previous exposures to higher
levels ofbutadiene than are now typically
experienced. It would take many years to
determine the carcinogenic risks associated
with current levels ofexposure ifmortality
studies were used as the basis for determin-
ing effects. Rodent studies of butadiene
could be used to estimate the carcinogenic
risk to humans; however, the apparent dif-
ferences between the sensitivities of rats
and mice to butadiene make this type of
assessment difficult. Species differences in
the carcinogenic response to butadiene may
be accounted for, at least in part, by paral-
lel differences in rates and patterns of
metabolism in mice, rats, and monkeys
(18,19). These differences suggest that the
order of sensitivity to the toxic effects of
butadiene appears to be mice>rats>
cynamologous monkeys. However, the
interpretation ofmetabolic and pharmaco-
kinetic data for cancer risk has been the
subject ofrecent debate (20,21).
How, then, can the safety of current
levels of occupational butadiene exposure
be assessed if mortality data for recent
exposure levels are not available, and the
applicability of the animal data is debat-
able? This dilemma can be addressed by
evaluating potentially exposed workers for
biological markers ofthe effects ofexposure
(22). The process of carcinogenesis
involves many steps, including the fixation
of mutations in oncogenes and suppressor
genes as exemplified in the progression of
colorectal carcinoma in man (23). In the
past decade, several assays for monitoring
the frequency ofsomatic cell mutations in
human blood cells have been developed for
use as biomarkers of the carcinogenesis
process (24-26). One of these assays,
which determines the frequency of muta-
tions at the hypoxanthine-guanine phos-
phoribosyl transferase (hprt) locus in
peripheral blood lymphocytes, was origi-
nally developed by Strauss and Albertini
(27). It has been refined into a useful tech-
nique for screening populations for expo-
sure to mutagenic agents (28-30).
Advances in chemical analytical tech-
niques have also led to the development of
sensitive methods for detecting, in body
fluids, the biotransformation products of
specific chemicals. Glutathione conjugation
products ofbutadiene have been quantita-
tively detected in the urine ofanimals (31)
and humans (32).
In this article we report the results ofa
preliminary study conducted to determine
whether both the biochemical evidence of
exposure to 1,3-butadiene and the possible
mutagenic effects of exposure could be
detected in a population ofworkers in a
butadiene extraction plant where exposure
levels are around 1 ppm. We have used a
chemical biomarker specific for butadiene
exposure (excretion ofa known metabolite
ofbutadiene in the urine) and a biomarker
for the mutagenic effect ofbutadiene (hprt
gene mutation). Elevated levels ofthe buta-
diene metabolite were detected in the urine
ofworkers in the production area, as com-
pared to workers in other areas of the
plant. A correlated increase in the fre-
quency ofhprtmutants was observed in the
lymphocytes ofthe exposedworkers.
Materials and Methods
StudyDesign
This study was designed as a pilot project
using a single sample to evaluate the fre-
quency of hprt mutant lymphocytes in
three groups of subjects: a) a group
exposed to 1,3-butadiene in a chemical
production plant, b) a group working in
the same plant but in areas where exposures
to butadiene were lower, and c) an outside,
nonexposed group consisting ofemployees
in the Department of Preventive Medicine
and Community Health at The University
of Texas Medical Branch (UTMB)
(Galveston, TX). Lymphocytes obtained
from the study subjects were assayed to
determine the frequency of hprt mutants
(referred to as the variant frequency or Vf)
(29,30,33).
Human Subject Recruitment
Study subjects were recruited from two
areas ofthe production plant where signifi-
cant exposures to butadiene had been
clearly documented and from two areas
where exposures to butadiene and other
chemicals were low. Potential study sub-
jects were not invited to participate ifthey
reported that they were cigarette smokers
or had been recently exposed to x-irradia-
tion or mutagenic drugs. All subjects were
asked to complete a questionnaire that
solicited information on the following sub-
jects: sex, age, job title and work location,
known chemical exposures at work, known
chemical exposures outside ofwork, history
of tobacco usage, current consumption of
alcoholic beverages, use ofcoffee and other
caffeinated beverages, general health, med-
ications, and consumption ofvitamin sup-
plements. At the time that blood and urine
samples were collected, a brief interview
was conducted to clarify and confirm
responses provided on the questionnaire.
Specimen Collection andProcessing
Blood was collected by venipuncture into
15-ml vacuum tubes containing sodium
heparin as an anticoagulant. Five tubes
(approximately 65 ml ofblood) were col-
lected from each subject. Blood samples
from the butadiene plant workers were
stored at room temperature in insulated
containers and returned to the UTMB lab-
oratory by automobile within 12 hr ofcol-
lection. Blood samples from the outside
control group were collected at the labora-
tory. Urine specimens of 100 to 200 ml
were collected in sterile plastic containers.
Aliquots ofabout 30 ml were transferred to
each of two 50-ml polypropylene cen-
trifuge tubes. The tubes and remaining
urine, in specimen containers, were frozen
on dry ice within 1 hr after collection. The
frozen specimens were transported to the
laboratory and stored at -18°C. Approxi-
mately 1 week after collection, one tube of
each sample was shipped to the Inhalation
Toxicology Research Institute (ITRI)
(Albuquerque, NM) for analysis to quanti-
tate urinary metabolites ofbutadiene.
At the UTMB laboratory, blood sam-
ples were fractionated by layering on
Histopaque (Sigma Chemical Co., St.
Louis, MO) and centrifuging to separate
lymphocytes, plasma, and erythrocytes.
Lymphocytes were cryopreserved, at 1
cells/ml, in RPMI 1640 with 50% heat-
inactivated fetal bovine serum (FBS) and
10% dimethylsulfoxide (DMSO). The
cells, in 1-ml cryotubes, were stored in liq-
uid nitrogen. Plasma and erythrocytes were
stored at -80°C. Plasma samples were ana-
lyzed for cotinine levels, using a radioim-
munoassay, in the laboratory of Dr. Helen
Van Vunakis (Brandeis University,
Waltham, MA). This cotinine assay is
highly specific and has a limit ofdetection
of2 ng/ml (34).
The/prtMutantLymphocyteAssay
Cryopreserved lymphocytes were
thawed and assayed for the frequency of
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hprt mutant lymphocytes using-an autora-
diographic procedure, which has been pre-
viously described (30,35). Briefly, the
lymphocytes were cultured in RPMI 1640
medium with 25 mM HEPES buffer, 100
U/mi penicillin, 100 jig/ml streptomycin
and 2 mM 1-glutamine (all from GIBCO),
2% phytohemagglutinin (PHA) (HA-15,
Burroughs Wellcome, Research Triangle
Park, NC), 20% HL-1 medium (Ventrex,
Costa Mesa, CA), 25% autologous plasma,
and either 2 x 10- M 6-thioguanine (TG)
in alkaline RPMI 1640 or an equal volume
ofalkaline RPMI 1640. Lymphocytes were
suspended in culture medium at 1 x
106/ml, 5 ml per flask (Falcon no. 3013),
and incubated for 24 hr at 37°C in a 5%
CO2 atmosphere. Tritiated thymidine
([3H]TdR), 25 pCi per flask (ICN, specific
activity 6.7 Ci/mmole) was added for an
additional 18 hr. Free nuclei were released
by the addition of 0.1 M citric acid. They
were washed in fixative (7:1.5 methano-
l:acetic acid), resuspended in 0.25 ml of
fixative and stored for at least 2 hr at 4°C.
The nuclei were counted with a Coulter
counter and the entire suspension from the
TG cultures was placed on one or two 18 x
18 mm coverslips previously mounted on
microscope slides. Approximately 2 to 3 x
105 nuclei from the nonselective cultures,
(without TG) were placed on a coverslip in
a similar manner. The slides were stained
with 2% aceto-orcein (GIBCO), dipped in
NTB-2 photographic emulsion (Kodak,
Rochester, NY) and stored at 4°C in light-
tight boxes for at least two days. They were
then developed with Kodak D-19. Slides
were coded to blind the scorer as to their
identity and were then scored by scanning
the entire coverslip microscopically to
determine the number oflabeled cells (M)
on all the coverslips prepared from the TG-
containing cultures from each subject. To
determine the labeling index (LI) in nonse-
lective cultures a differential count of2500
cells was made and the numbers oflabeled
and unlabeled cells were counted. The
number of evaluatable cells (N) is the
number of cells that had the potential to
become mutants. This term is calculated as
the total number of cells recovered from
TG cultures (as determined by the Coulter
count) multiplied by the proportion of
cells that could respond to PHA (the LI).
The Vfis calculated as MIN.
StatisticalMethods
Comparison ofexposure groups was carried
out by two methods to determine whether
significant differences in Vf occurred
among them. First, a weighted average
called a ratio estimator (Rf) (36,37) and its
standard error [SE(Rf)] were calculated. In
calculating the Rf, the Vffor each subject
was given a weight proportional to the
number ofevaluatable cells obtained from
that subject. A confidence interval (95 or
99%) was computed for each group's Vfas:
Vf=[Rf±tSE(Rf)] 95 (or.99)
where t is the Student's t corresponding to
(n-1) degrees of freedom and the interval
of95% (or 99%). Details ofthe calculation
ofRfand SE(Rf) have been published pre-
viously (29). A difference between groups
at a particular level ofsignificance is indi-
cated by a lack ofoverlap ofthe confidence
intervals for the groups' Vfs. Second, the
mean Vfs among exposure groups were
compared using analysis ofvariance. In this
analysis, the square-root ofthe Vfwas used
as the dependent variable to better approxi-
mate normality and better stabilize inter-
subject variability.
To investigate the possibility that age or
length of time working in this plant could
explain all or part of the Vf results, we
examined the distribution of ages and
longevities in the exposure groups as well as
the correlation between age or longevity
and Vf. Similarly, to determine whether
metabolite level, as a measure ofexposure,
was related to Vfwe investigated the corre-
lation ofVf and metabolite concentration
in urine. This correlation was investigated
using the square root ofVf and the loga-
rithm ofthe metabolite concentration.
Results
Population Description
Samples ofblood and urine were obtained
from 20 subjects at the chemical plant and
9 subjects at UTMB. Of the 20 workers
employed at the butadiene production
plant, 7 worked in areas or at jobs that
were considered likely to expose them to
higher levels of butadiene than in other
parts of the plant. These workers were
process operators or rovers in the "north"
and "south" butadiene production areas.
Ten individuals worked in areas where the
likelihood of exposure to butadiene was
considered to be low. These areas included
the central control area for the production
units, and the steam power and water plant
with its control area. In addition, three
individuals (process rovers) had duties
which required that they spend time in
both the production areas and the central
control area. hprt Mutant lymphocyte
assays were successfully conducted on six of
the seven high-exposed individuals and two
ofthe three individuals with variable expo-
sure. At present, samples from five of the
low-exposed and six of the nonexposed
subjects have been analyzed. The subjects
with variable exposure were grouped with
the high-exposure individuals to total eight
subjects in this group. The distributions of
ages and years of work in the plant are
summarized for each exposure group in
Table 1. The ages of the high- and low-
exposed workers had a similar distribution.
In each of these two groups, one older
worker (57 and 54 years of age, respec-
tively) with manyyears ofseniority (33 and
32.8 years) contributed to the dispersion of
the ages and years ofwork ofthese groups.
The median age was 35 and the median
years ofwork was 3.8 for the high-exposed
group, and the age was 40 and work years
3.4 for the low-exposed group. The median
age in the nonexposed group was 36.
ExposureDescription
Exposures to butadiene and other chemi-
cals were estimated from an air sampling
study conducted by the industrial hygiene
department of the company and provided
to the investigators by the workers' union.
Between January 14 and July 21, 1991,
165 air samples were collected using
Sensidyne no. 174 L low-range detector
tubes, and the samples were analyzed by
gas chromatography for butadiene, ben-
zene, and methyl-tertiary-butyl ether
(MTBE). Both area and personal samples
were collected. All area samples were col-
lected for 8 hr. Some ofthe personal sam-
ples were collected for only 15 to 20 min
intervals, presumably to evaluate exposures
Table 1. Descriptive statistics for exposure groups.
Exposure Sex Race aYears
group N M F W B H Age± SD In plant± SD
Nonexposure 6 6 0 4b 0 2 36.5(37)b± 5.4 N/A
Low-exposure 5 4 1 3 2 0 41.7(42)± 9.4 9.3± 13.18
Int-exposure 2 2 0 2 0 0 51± 8.5 17.7 ± 21.7
High-exposure 6 6 0 5 1 0 33.8(34) ± 3.8 3.3 ± 1.5
Abbreviations: W, white; B, black; H, hispanic. aWhites include two Asians; bNumbers in parentheses)indicate
median values.
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Table 2. Butadiene levels in workplace air. Area sam-
ples collected over approximately 8 hr.
Work Butadiene, ppm Distribution,appm
area N mean ± SD <1 1-10 >10
North 31 3.18 ±7.13 23 4 4
unit
South 29 3.89 ± 7.60 21 3 5
unit
Central 7 0.03 ± 0.03 7 0 0
control
aDistribution of numbers of samples falling in the indi-
cated exposure ranges.
related to specific activities. The areas stud-
ied were the north and south production
units, the MTBE production unit (which
was not evaluated in this study), and the
central control area. The steam power and
water plant was not evaluated. Table 2
summarizes the results obtained for butadi-
ene from the long-term area sampling.
While the mean area and personal butadi-
ene values obtained in the production areas
were about 3.5 ppm, the majority of the
individual samples showed concentrations
below 1 ppm. The highest value obtained
for an area sample in the production areas
was 30 ppm. In central control the mean
values were much lower (0.03 ppm) and
the highest value obtained was 0.06 ppm.
Levels for benzene were very low, averaging
0.002 ppm in the south area, 0.02 ppm in
the north area, and 0.01 ppm in central
control. Levels for MTBE were also low,
with none detected in the south area or
central control, and 0.006 ppm in the
North area.
hprtMutantLymphocyte Frequencies
The results of the analysis for hprt
mutant lymphocyte frequencies are pre-
sented in Table 3. The frequency of
mutant lymphocytes (the Vf) was signifi-
cantly elevated in the high-exposed group
as compared to both the low-exposed
group and the nonexposed group. The
weighted mean Vf (see "Statistical
Methods") was 3.84(± 0.70) x 10-6 per
evaluatable cell in the high exposed group,
1.16(± 0.27) x 10-6 in the low-exposed
group, and 1.03(± 0.07) x 10-6 in the non-
exposed groups. As indicated by the confi-
dence intervals presented in Table 3, the
high-exposed group was significantly
higher than both the nonexposed group
(p<0.01) and the low-exposed group
(p<0.05). The low-exposed and nonex-
posed groups were not significantly differ-
ent from each other.
The same result was obtained when dif-
ferences in exposure groups were investi-
gated by analysis ofvariance. Differences
among the three groups were significant
(p<0.05) and the high-exposed group was
significantly different from the low-exposed
group (p<0.03) and the non-exposed group
(p<0.01). The low-exposed and nonex-
posed groups were not significantly differ-
ent from each other.
We found no correlations of hprt Vf
with age or years ofwork in the plant. The
nonsmoking status ofthe subjects was con-
firmed by analysis for plasma cotinine. The
two individuals with high cotinine values
(305 and 332 ng/ml of plasma) reported
use ofone-fourth to one-third ofa 1 oz box
ofsnuffdaily, while the two subjects with
low (31 and 72 ng/ml), but detectable,
cotinines reported occasional snuff use.
Nicotine in snuff should be readily
absorbed resulting in elevated cotinine lev-
els; however, the mutagenic combustion
products present in cigarette smoke would
be absent.
Urine specimens were analyzed for
butadiene-specific metabolites at ITRI,
(Albuquerque, NM). Details ofthis analy-
sis are being reported separately (32). A
single metabolite, 1,2 dihydroxy-4-(N-
acetylcysteinyl)butane, was detected. The
urinary concentrations of this butanediol
conjugate for each subject are listed in
Table 3 with the results from the lympho-
cyte samples analyzed for hprt mutants.
The exposure group means (± SD) were
2927 ± 3995, 554 ± 152, and 320 ± 138
ng/ml for the high-, low-, and nonexposed
groups respectively. By analysis ofvariance
the intergroup differences were significant
Table 3. Frequencies of hprtmutant lymphocytes and butanediol metabolite levels in non-smoking butadiene plantworkers and controls.
Evaluatable hprt Plasma Dihydroxybutane Weighted meanb
Labeling Total cells, Cells labeled Vf, cotininea, urinary Vf ± SE, x 10.6
index x106 X106 cells X106 ng/ml metabolite [95 or99% confidence intervals]
Exposed workers
0.149 7.170 1.060 1 0.94 <2 564 3.84±0.7
0.235 6.540 1.537 2 1.30 <2 514
0.133 8.635 1.148 3 2.61 <2 1633
0.169 19.380 3.275 10 3.05 305 1179
0.128 14.692 1.881 7 3.72 <2 2002
0.178 12.572 2.238 9 4.02 31 3879 Cl99= 1.74, 4.05
0.141 11.641 1.641 12 7.31 <2 1193 C195=2.39,5.79
0.135 7.424 1.002 9 8.98 <2 12,456
Low-exposed worker controls
0.171 15.023 2.569 2 0.78 <2 297 1.16 ±0.27
0.104 9.744 1.013 1 0.99 332 661
0.147 6.508 0.957 1 1.04 2 533
0.079 11.439 0.904 1 1.11 <2 595 Cl99=0.19-2.03
0.181 7.930 1.435 3 2.09 <2 640 Cl95=0.64, 1.68
Outside controls
0.206 18.217 3.753 3 0.80 75 186 1.03 0.07
0.151 19.761 2.984 3 1.01 <2 286
0.200 14.688 2.938 3 1.02 <2 149
0.183 15.148 2.772 3 1.08 <2 357
0.057 16.314 0.930 1 1.08 <2 487 [Cl99=0.81-1.241
0.364 14.036 5.109 6 1.17 <2 455
aPlasma cotinine determination: Detection limit is 2 mg/ml, two subjects in whom >20 mg/ml cotinine was detected reported moderate use of snuff. Two subjects with coti-
nine values of 305 and 332 reported using 1/4 of a 1 oz box of snuff daily. bSee definition in Statistical Methods. CSignificantly higher than the low- and the nonexposed
groups, p<0.05.
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Figure 1. Correlation between levels of 1,2-dihydroxy-
4-(n-acetylcysteinyl-S)butane metabolite in urine and
the frequency of hprt-deficient mutants per million
evaluatable lymphocytes (Vf) in study subjects.
Metabolite concentrations are plotted on a log scale.
Exposure groups: nonexposed controls (V); low-
exposed (N); high-exposed (*). See text for descrip-
tion of exposure groups.
(p<0.002) with the high exposed group sig-
nificantly different from the lowexposed
group (p<0.03) and the nonexposed group
(p<0.002). The low-and nonexposed
groups were not significanlty different. The
log of the concentration of the metabolite
correlated strongly with the square root of
the frequency of hprt mutants (r = 0.85).
Figure 1 shows the relationship between
hprtVf and butadiene metabolite concen-
tration.
Discussion
This investigation was designed as a pilot
study to evaluate the feasibility ofconduct-
ing a larger study to determine whether
current levels of occupational exposure to
butadiene are capable ofinducing increased
frequencies of single gene mutations or
other types ofgenetic damage. The sample
size was small, but we were fortunate in
having detailed air sampling data available
from the worksite, and we also had the
opportunity to compare the results of the
hprt mutant lymphocyte assay with levels
of a butadiene-specific metabolite excreted
in the urine.
The selection ofwork areas from which
to recruit high- or low-exposed subjects
was based initially on discussions with
plant personnel who were familiar with the
operations of the facility. The selections
were supported by the air sampling data,
which indicated that the mean butadiene
levels in the north and south production
areas were about 100 times higher than in
the low-exposed central control area. A
similar selection ofwork areas had formed
the basis for defining higher and lower
exposure areas in earlier mortality studies
ofworkers in the same facility (17,38).
The results of the air sampling survey
appear to be generally consistent with other
sampling studies ofbutadiene production
plants (2). In general, the area results indi-
cate that exposure levels in production
areas were typically at or below 1 ppm,
with occasional samples indicating higher
exposures. In both the north and south
production areas, three offour samples and
three of five samples over 10 ppm (Table
2) were obtained during single periods of
about 2 weeks rather than being evenly dis-
tributed throughout the period ofthe sur-
vey. The air sampling data were collected
between January and July 1991, while the
blood and urine samples were obtained at
the end of October 1991. Consequently,
the air sampling results cannot be used to
determine actual levels ofexposure during
the periods oftime that are significant for
the mutation and metabolite analyses.
Thus, the air sampling data indicate the
patterns ofexposure typically encountered
in the plant within a few months of the
time at which blood and urine specimens
were collected for this study.
It should be noted that all ofthe sam-
ples were far below the current OSHA per-
mitted exposure limit (PEL) of 1000 ppm
(29 CFR 1910.1000) and that almost all
samples were within the in-house standard
of 10 ppm currently used by the plant. A
majority of the samples were below the
proposed OSHA PEL of2 ppm (39).
The frequencies of hprt mutant lym-
phocytes were significantly elevated in the
high-exposed group as compared to either
the low-exposed or the nonexposed group.
The correlation between exposure group
assignment and Vf (using the square root
transformation) was r=0.72 (p<0.001).
Although the number ofsubjects was low,
the Vfs for the high-exposed group appear
to fall into three categories. Two subjects
had values that were not distinguishable
from the low-exposed or nonexposed
groups. Four subjects had Vfs which were
elevated about 2- to 4-fold over the nonex-
posed control mean, and two subjects had
elevations of7- to 8-fold over the control
group. The individual with the highest Vf
(and the highest butadiene metabolite
level) (Figure 1) was assigned to a job with
a higher risk ofexposure than normal day-
to-dayjob assignments during part ofthe 6
weeks preceding blood sample collection. It
is likely that his exposure level was higher
than is typical for normal activities in the
production areas. We are not aware ofany
specific activities that might explain the
high Vfofthe other individual with an ele-
vated Vf. Of the two process rovers who
spend time in both high- and low-exposure
areas, one had a Vf of 0.94 x 10-6 and a
metabolite level of564 while the other had
a Vfof 3.05 x 10-6 and a metabolite level
of 1179. These values may reflect the vari-
ety ofexposures that individuals in this job
assignment may experience. It appears
probable that the middle group ofelevated
Vfvalues are reflective oftypical day-to-day
exposures in the production areas.
The high correlation between the Vfs
and the levels of urinary metabolites
strengthens the impression that the eleva-
tion in Vfis a result ofbutadiene exposure
rather than being due to some other unde-
fined factor. The strength ofthe correlation
is greater than we expected in that the sig-
nificant periods ofexposure for producing
elevated hprt mutant lymphocyte frequen-
cies and elevated levels ofurinary metabo-
lites are somewhat different. In earlier
studies of patients receiving mutagenic
drugs or radiation treatments (29,30) we
found that the time interval between the
onset of a mutagen exposure and the
appearance of increased frequencies of
mutant lymphocytes was about 2 weeks.
We also found that mutant frequencies
declined to near pretreatment levels by
about 6 weeks following the termination of
acute exposures. Based on these observa-
tions, the critical time period for the induc-
tion ofmutant lymphocytes by exposure to
mutagens would begin about 6 weeks prior
to the time ofblood sample collection, and
exposures occurring within 1 or 2 weeks of
sampling would not significantly affect the
Vf. In contrast, metabolites of butadiene
should be excreted rapidly, so their levels in
urine would be a reflection of exposure
only during the previous 24 hr. Since the
urine specimens were collected at the end
ofthe work shift, the metabolite levels are
probably reflections of exposures during
that shift. The fact that the metabolite lev-
els and Vfs are so highly correlated suggests
that patterns of exposure were probably
fairly consistent over the 6-week period
endingwith the dayofsample collection.
The autoradiographic assay for hprt
mutant lymphocytes has both advantages
and disadvantages when compared to the
more complex version ofthe assay which is
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based on the long-term growth ofclones of
mutant lymphocytes in culture (40). The
clonal assay permits the further biochemi-
cal and genetic characterization ofputative
mutant clones to establish that they are
true mutants. It is possible to sequence the
DNA of the mutant cells to identify spe-
cific genetic changes and additional work
can be done to determine whether individ-
ual clones are unique in origin or siblings
from a clone of cells arising in vivo (41).
While the autoradiographic assay does not
provide viable mutant cells for such analy-
ses, it is a more appropriate technique for
screening populations. The autoradi-
ographic method is less dependent on con-
trol ofvariables such as those related to
longer-term lymphocyte cultures and it can
be standardized more readily. Because cells
are routinely cryopreserved prior to assay,
they may be stored until a convenient time
for analysis. In our experience, the Vfs of
normal controls have been very consistent
(29,42,43) when compared to the greater
degree ofvariability observed in the clonal
assay (44). This consistency, which was
also observed in the present study, is criti-
cal to the detection of significant differ-
ences in Vf in small populations. The
assay has also proven very sensitive in mice,
detecting mutations induced by subacute
inhalation exposures to benzene at concen-
trations as low as 40 ppb (45).
The use of two biologic markers and
the availability ofair sampling data permit-
ted much more significant information to
be obtained from a small population than
would have been possible ifonly one end
point had been evaluated. The two biologi-
cal markers were strongly complimentary
ofeach other because the butanediol conju-
gate was specific for the chemical ofinter-
est, butadiene, while the other detected a
general, but important, biologic response,
gene mutation. The analysis for urinary
metabolites demonstrated that exposures to
butadiene occurred, and provided useful
information about human metabolism of
butadiene (32). The observation ofa corre-
lated increase in hprtVfindicates that these
exposures are capable of inducing muta-
tions, a biological response which connotes
an increased risk ofcancer.
The increase in hprtVfobserved in this
study can be placed in context by compar-
ing it to the effects of cigarette smoking
and mutagenic medical treatments, which
we have evaluated with the same assay. The
increase in hprtVfthat we have previously
observed in adult cigarette smokers, based
on our results to date, has been similar to
the increase related to butadiene exposure
(Vffor nonsmokers 1.33 (± 0.10) x 10-6;
n = 33; Vffor smokers 4.61(± 0.43) x 10-6;
n=15). Comparable proportionate increases
in Vfwere seen in cord blood lymphocytes
from newborns born to smoking, as com-
pared to nonsmoking mothers (43). In
addition, baboons trained to smoke ciga-
rettes showed a similar 3-fold increase in Vf
at the end ofa 4-month period ofsmoking
as compared to a presmoking sample (46).
In contrast, patients receiving radiation
therapy had 5- to 15-fold increases in Vfs 2
to 3 weeks after onset ofexposure to cumu-
lative doses ofabout 900 cGy (30). These
comparisons indicate that the increased
hprtVfs associated with current levels of
occupational exposure to butadiene are
similar to those associated with cigarette
smoking.
The dihydroxy-butane conjugate found
in human urine is one oftwo N-acetycys-
teine conjugates of butadiene excreted in
the urine of other mammals exposed to
high concentrations ofbutadiene. The pro-
portion of this conjugate in the urine of
mice, rats, hamsters, and monkeys increases
in proportion to the levels ofhepatic epox-
ide hydrotase (31). While the human
metabolic pattern appears more like that of
monkeys or rats than that ofmice, the high
correlation ofbutadiene metabolite excre-
tion with hprtVf indicates that genotoxic
intermediates are being formed in propor-
tion to the level of formation of this
metabolite. The correlation ofthe metabo-
lite excretion pattern and the induction of
mutations in humans exposed to low levels
ofbutadiene indicates that the role ofbuta-
diene metabolism and pharmacokinetics in
susceptibility to butadiene toxicity (19)
should be reevaluated.
Our results at this time indicate that,
although current exposure levels are at or
below the proposed OSHA PEL for buta-
diene, they may not be sufficiently low to
protect workers from the health risks that
are associated with mutagen exposures. We
are currently conducting tests for other
biomarkers ofgenetic damage using addi-
tional biological materials obtained during
the sample collection on which the current
results are based. Additional studies will be
needed, and are in progress, to establish the
consistency of these effects and to better
define the relationship between hprt Vf,
butadiene exposure level, and work activ-
ity. Furthermore, research to better define
the relationship between mutant frequency
and biologically effective dose is needed.
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